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Introduction: Chemotherapy-induced hepatic injuries (CIHI) are an increasing problem facing hepatic
surgeons. It may be possible to predict the risk of developing CIHI by analysis of genes involved in the
metabolism of chemotherapeutics, previously established as associated with other forms of toxicity.
Methods: Quantitative reverse transcriptase-polymerase chain reaction methodology (q-RT-PCR) was
employed to quantify mRNA expression of nucleotide excision repair genes ERCC1 and ERCC2, relevant
in the neutralization of damage induced by oxaliplatin, and genes encoding enzymes relevant to
5-flurouracil metabolism, [thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimi-
dine dehydrogenase (DPD)] in 233 hepatic resection samples. mRNA expression was correlated with a
histopathological injury scored via previously validated methods in relation to steatosis, steatohepatitis
and sinusoidal obstruction syndrome.
Results: Low-level DPD mRNA expression was associated with steatosis [odds ratio (OR) = 3.95, 95%
confidence interval (CI) = 1.53–10.19, P < 0.003], especially when stratified by just those patients exposed
to chemotherapy (OR = 4.48, 95% CI = 1.31–15.30 P < 0.02). Low expression of ERCC2 was associated
with sinusoidal injury (P < 0.001). There were no further associations between injury patterns and target
genes investigated.
Conclusions: Predisposition to the development of CIHI may be predictable based upon individual
patient expression of genes encoding enzymes related to the metabolism of chemotherapeutics.
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Introduction
Chemotherapy-induced hepatic injuries (CIHI) comprising sinu-
soidal injuries and chemotherapy associated fatty liver diseases
[chemotherapy associated simple steatosis (CASS) and chemo-
therapy associated steatohepatitis (CASH)] are an increasing
problem facing hepatic surgeons operating on patients with
colorectal liver metastases (CRLM) who have been subjected to
chemotherapy.1
Significance of CIHI
Steatosis
Simple steatosis (fatty degeneration of hepatocytes) increases the
overall rate of surgical complications up to twofold after a hepatic
resection,2 and is an independent predictor of morbidity.3 Infec-
tive complications3–5 and increased blood loss2,6,7 are particular
problems after resection of steatotic livers.
Steatohepatitis
The presence of steatohepatitis (fatty degeneration of hepatocytes
with inflammatory changes) increases the risk of hepatic failureThis paper was presented at the AHPBA 2011 meeting in Miami, FL, USA.
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after a major hepatic resection.8–10 Steatohepatitis is also clearly
associated with an increased overall post-operative mortality with
an almost 10-fold increased 90-day mortality after hepatic resec-
tion in patients with this injury (mortality 14.7% vs. 1.6% in a
cohort of 406 patients11).
Sinusoidal injury
Morbidity after a hepatic resection is significantly higher in
patients with sinusoidal obstruction syndrome (up to 40% vs.
6.3% in a cohort of 90 patients12) although mortality is
unchanged.13 Blood loss appears to be the most important mecha-
nism through which sinusoidal injury increases morbidity. Oxali-
platin is particularly associated with the development of
sinusoidal injury14 and is also associated with increased transfu-
sion requirements compared with patients receiving 5-flurouracil
(5FU) and leucovorin or no chemotherapy.15
Interaction between genetic parameters and toxicity
The clinical significance of CIHI is only now being realized, in
parallel with the greater utility of chemotherapy before a hepatic
resection. While much work has already been done to examine the
toxic side effects of chemotherapy on other organ systems result-
ing in, for example, hematological, gastrointestinal16 or neuro-
pathic toxicity,17 considerably less is known about the relationship
between chemotherapy and hepatic toxicity.
Toxicity in other organ systems has been associated with
various genetic polymorphisms and varying expression of certain
key enzymes involved in the metabolism of chemotherapy or the
manifestations of drug action. Specifically, the nucleotide excision
repair (NER) system is known to be key in regulating the toxicity
of platinum-based compounds such as oxaliplatin to tumoural
tissue, and both ERCC1 and ERCC2 levels have been shown to be
genetic susceptibility factors.18,19 Toxicity to normal host hepatic
tissue based on varying expression of these enzymes has not been
examined.
With respect to 5FU, varying expression of thymidylate syn-
thase (TS) (inhibition of which forms the key mechanism of
action of 5FU) is known to be of prime importance in the tumoral
response and host toxicity.16 Dihydropyrimidine dehydrogenase
(DPD) is the most important enzyme responsible for the metabo-
lism of 5FU,20,21 and patients with reduced activity of this enzyme
are at an increased risk of toxicity from 5FU. Similarly, varying
expression of tumoural and host thymidine phosphorylase (TP)
[also known as endothelial cell growth factor (ECGF)] has been
correlated with response and toxicity, although often with con-
flicting results.22
The genes described above are prime candidates warranting
evaluation to explore hepatic toxicity from 5FU and oxaliplatin
containing chemotherapies. We hypothesize that low expression
of any of these enzymes may predispose to the development of
CIHI. Here, we correlate mRNA expression of these enzymes with
the development of significant CIHI (namely, steatosis >33%,
presence of steatohepatitis and sinusoidal injury involving >1/3 of
the hepatic lobule) as assessed histologically using validated
scoring systems23 on retrospective tissue samples.
Methods
Patients
Consecutive patients having undergone hepatic resection for any
pathology between September 2001 and November 2009 were
retrospectively identified from a prospectively collected tissue
bank at Peter MacCallum Cancer Centre. Additional patients who
had undergone hepatic resection for CRLM at The Alfred Hospital
between May 1995 and September 2009 were identified from a
database detailing these patients’ clinical and operative outcomes.
Chemotherapeutic administration data were collected from pre-
viously collated databases, retrieved from review of clinical history
or extracted from dispensing databases of the pharmacy depart-
ments of the relevant hospitals.
Histological assessment
Haematoxylin and Eosin (H&E) stained slides of non-tumorous
liver were available for all patients, and Masson trichrome stained
slides were generated from formalin-fixed paraffin-embedded
(FFPE) tissue blocks containing non-tumorous liver from either
the tissue bank specimens or the pathology archive from Peter
MacCallum and The Alfred Hospitals, respectively. Both H&E and
Masson’s slides were independently and blindly scored for the
degree of steatosis, presence or absence of steatohepatitis [as
defined by non-alcoholic fatty liver disease (NAFLD) activity
score >223 with >5% steatosis], and degree of sinusoidal dilation,24
by two independent pathologists blinded to the patient’s history.
For the purpose of correlation, significant steatosis was considered
>33%, and significant sinusoidal injury was considered grade 2
(centrilobular involvement up to 2/3 of the lobule) or grade 3
(complete lobular involvement).18
mRNA expression
RNA was extracted from either fresh frozen or FFPE tissue as
available. Briefly, fresh frozen normal hepatic tissue was lysed in
Trizol (Invitrogen, Carlsbad, CA, USA) and RNA extracted using
the RNeasy minikit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions, or from FFPE blocks using the
RNeasy MinElute kit (Qiagen) according to the manufacturer’s
instructions. Reverse transcription (RT) to cDNA was carried out
first by mixing 0.5 mg sample RNA (concentration 100 ng/ml) and
0.5 mg random hexamers (500 mg/ml, Promega, Madison, WI,
USA) in a 6-ml reaction then incubating at 70° for 5 min. To this,
0.5 ml (200 U/ml) M-MLV RT (Promega) was added with 20 ml
M-MLV buffer (Promega), 5 ml of 10 mM dNTP and diethylpy-
rocarbonate water (DEPC) to a total of 50 ml, and subsequently
incubated at 42° for 2 h.
Expression of each of the target genes was assessed by quanti-
tative real-time RT-polymerase chain reaction (PCR). Target gene
primers were designed to cross intron/exon boundaries and
obtained from Geneworks (Melbourne, Australia), primer
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sequences are given in supplementary Table S1. Samples were
assessed in duplicate in a Roche Lightcycler 480 real-time quan-
titative PCR machine and compared with the housekeeping gene
GAPDH. Reactions consisted of 5 ml SYBR green reagent (Roche,
Mannheim, Germany), 1 ml of 100 mM target primer and 0.5 ml of
sample cDNA made up to a total volume 10 ml with milliQ water.
A gastric cancer cell line, AGS, was used as a positive control
(having previously demonstrated expression of all targets). A no
template negative control was utilized with each run. After an
initial activating step for 15 min at 95°, 50 cycles of 95° (15 s), 60°
(30 s) and 72° (30 s) were carried out followed by a final melt stage
at 95°. Single products were confirmed using melt-curve analysis
for each sample then a CT value was generated using the second
derivative maximum method. Target: reference ratios were then
calculated as described elsewhere.25 Ratios were normalized to
AGS for each sample.
Statistical analysis
mRNA expression data were discarded for patients in whom the
CT value indicated that only primer had been amplified when the
sample had been run in duplicate on three separate occasions.
Associations between presence or absence of significant injuries
and mRNA expression of target genes was tested by Fisher’s exact
test with expression levels considered as categorical variables,
groups formed by dividing samples into halves by mRNA expres-
sion ratios (representing high or low expressors). Odds ratios
(ORs) [with 95% confidence intervals (CIs)] were generated
accordingly. The ratio of target gene to housekeeping gene mRNA
expression was also assessed as a continuous variable, with differ-
ences detected using the t-test. Analyses were done among all
patients and among only those treated with chemotherapy fol-
lowed by surgery. In both analyses results were considered signifi-
cant when P < 0.05. Patients who had a repeat hepatectomy at a
later date than their primary heptatectomy had tissue included
from both operations.
Results
The cohort consisted of 221 patients and 233 samples of non-
tumoural hepatic tissue (12 patients provided two samples from
two separate hepatectomies), 62.4% of which was FFPE, the
remainder being fresh frozen tissue. High-grade steatosis (steato-
sis >33%) was found in 18.0% of the cohort overall. High-grade
sinusoidal dilation (grade 2 or 3, involving >1/3 lobule) was seen
in 15.4% and the rate of steatohepatitis was 4.3% (Table 1).
Sixty per cent of patients (N = 133) had been exposed to che-
motherapy. 5FU was the most common agent used, and 1/3 of the
cohort was also known to have had oxaliplatin administered (con-
currently with 5FU). No patient in this cohort was documented as
having been administered irinotecan (Table 2). Chemotherapy
was ceased before hepatic resection in all cases by at least 4 weeks.
RNA extracted from FFPE blocks was of inferior quality to that
extracted from fresh-frozen tissue, and the raw CT value of each
target gene was significantly higher for samples that were
extracted from FFPE blocks (data not shown). However, the ratio
of target: reference expression was not significantly different when
compared between FFPE and fresh-frozen samples (supplemen-
tary Table S2). Therefore, the ratio data describing the sample as
high or low expressing were combined without distinction.
The rates of injury when comparing high vs. low expression of
target genes for all patients demonstrated a statistically signifi-
cantly higher rate of steatosis in patients with low expression of
DPD (OR = 3.95, 95%CI 1.53–10.19, P < 0.003), Fig. 1 and
Table 3. This was also true for the subgroup of patients who were
administered chemotherapy (OR = 4.48, 95%CI 1.31–15.30, P =
0.02). The proportion of samples that were from FFPE blocks was
57.9% for DPD (not statistically significantly different from
cohort overall – where 62.4% of samples were from FFPE tissues).
When the target: reference ratios were considered as a continu-
ous variable, again lower expression of DPD was associated with
steatosis in a statistically significant way, and sinusoidal injury was
associated with lower levels of ERCC2, Table 4.
There were no further associations between injury patterns, and
mRNA expression of ERCC1, ERCC2, DPD or TS and TP.
Discussion
The liver is one of the most metabolically active organs in the
human body, with multiple enzyme systems called upon to
detoxify, activate, metabolize and/or excrete ingested xenobiot-
ics.24 These enzyme systems are complex, polymorphic, inducible
and there is much potential for alternate pathways of metabolism.
Table 1 Prevalence of hepatic injury among hepatic samples
Injury Definition Per cent
(N samples)
Steatosis
Grade 0 0% 24.4% (57)
1 >0–5% 30.8% (72)
2 >5–33% 26.9% (63)
3 >33–66% 12.0% (28)
4 >66% 6.0% (14)
Sinusoidal injury
Grade 0 Nil 70.5% (165)
1 up to 1/3 lobular involvement 14.1% (33)
2 >1/3–2/3 lobular involvement 6.8% (16)
3 >2/3 to complete
lobular involvement
8.6% (20)
Steatohepatitis
Presence steatosis > 5%, NAFLD
activity score* > 2
4.3% (10)
*NAFLD activity score = sum of scores for: Mallory bodies + lobular
inflammation + hepatocyte ballooning + perisinusoidal fibrosis (each
factor scored 0 = absent, 1 = focal involvement of some lobules, 2 = focal
involvement of most lobules, 3 = focal involvement of most or all, with
diffuse involvement of some or most).23
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Some enzyme cascades of relevance in other organs (in which
there is more limited ability to detoxify substances using other
pathways) may be less relevant in the development of hepatic
toxicity. The liver may simply divert the metabolism of any given
agent through alternative enzyme systems when the primary
system is deficient or absent. Thus, enzymes expected to be of
relevance based on correlations from other organ or tissue toxicity
may not be found to be important in hepatic toxicity.
Here we have demonstrated a significant correlation between
low mRNA expression of DPD and steatosis. This appears to be
true for steatosis in general: low expression of DPD is associated
with a 3.95-fold increase in the rate of steatosis in our cohort
Table 2 Agents used when chemotherapy administered
Agent Given per cent (N) Not given per cent (N) Data missing per cent (N)
Chemotherapy in cohort overall 60% (133) 40% (88)
5-FU 70% (93) 0.7% (1) 29.3% (39)
Oxaliplatin + 5FU 33%* (44) 34% (45) 33% (44)
Irinotecan 0% 77.4% (103) 22.6% (30)
*All those who had oxaliplatin also had 5-FU.
OR. (95% CI) for steatosis P-value
0.003
0.02
3.95
4.48
All patients
Chemotherapy only
0.5 1 2 5 10 20
Figure 1 Odds ratios (ORs) of low dihydropyrimidine dehydrogenase (DPD) mRNA expression and risk of high grade steatosis
Table 3 mRNA expression and odds ratio (OR) for high-grade steatosis [significant associations (P < 0.05) are in bold text]
N Steatosis Expression: OR (95% CI) P-value
Low High
DPD All patients 134 + 19 7 3.95 (1.53–10.19) 0.003
- 44 64
Chemo only 75 + 14 4 4.48 (1.31–15.30) 0.02
- 25 32
ERCC1 All patients 107 + 9 8 1.23 (0.44–3.47) 0.70
- 43 47
Chemo only 60 + 6 5 1.47 (0.40–5.48) 0.56
- 22 27
ERCC2 All patients 60 + 7 7 1.0 (0.33–3.31) 1.0
- 23 23
Chemo only 37 + 5 6 0.83 (0.20–3.43) 0.80
- 13 13
TS All patients 55 + 6 2 4.42 (0.81–24.28) 0.07
- 19 28
Chemo only 33 + 4 1 4.0 (0.40–40.43) 0.21
- 14 14
TP All patients 85 + 7 8 0.93 (0.30–2.83) 0.89
- 34 36
Chemo only 53 + 4 6 0.84 (0.21–3.42) 0.81
- 19 24
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overall (P < 0.003). The effect is more pronounced when analysing
just those patients having received chemotherapy, with an OR for
development of steatosis of 4.48 (P < 0.02). As far as we know, this
is the first time this association has been demonstrated. Low
expression of DPD has been correlated previously with other
forms of organ toxicity,26,27 and to this list, hepatic toxicity in the
form of steatosis may now be added. There was no correlation
between DPD expression and sinusoidal injury or steatohepatitis
in this cohort. While an association has been shown, causation
remains to be proven, as these tissues were collected at the time of
hepatic resection after treatment with chemotherapy. Therefore,
whether the low expression of DPD predisposes to steatosis, or
whether steatosis results in lower expression of DPD, remains
unproven.
DPD is the rate-limiting enzyme in the metabolism of 5FU25,
and its effect on detoxifying this agent in the liver appears to be
important, therefore, in the prevention of liver injury, manifesting
as steatosis when this enzyme is only present at low levels. The
reasons as to why this injury pattern predominates, and sinusoidal
injuries do not appear to be associated remain unclear. Steatosis is
a ‘common denominator’ pathological phenotype,28 and is the end
result of many injurious agents. Exactly why the liver exhibits a
steatotic response when it is unable to detoxify 5FU efficiently is
unknown.
In spite of its importance in other organ toxicity, we found no
correlation between TS and hepatic toxicity. 5FU is more effective
against tumoral tissue and more toxic to normal tissue generally
in the presence of low expression of TS29. However, livers exam-
ined in this cohort did not exhibit any pathological response when
patients with low hepatic expression of TS were exposed to 5FU.
This could be because normally, hepatic tissue is a stable tissue
type, not actively involved in regeneration and DNA synthesis.
Theoretically, 5FU acting through inhibition of TS (thereby inhib-
iting DNA synthesis) may not affect organs that are not actively
synthesizing DNA. Of course, after hepatic resection, the liver does
indeed switch on its regenerative capacity. However, in this imme-
diate post-operative setting, patients are not administered 5FU,
and any effect from earlier inhibition of DNA synthesis may no
longer be in effect.
High-grade sinusoidal injury is associated with low levels of
ERCC2 although the evidence for this is weakened in this cohort
by small numbers of patients. The association between ERCC2
(key in the repair of damage induced by oxaliplatin), and sinusoi-
dal injury (which is the hallmark injury induced by oxaliplatin)
clearly deserves further investigation, but no decisive statements
about causality or predisposition can be made at this stage.
The major limitation of this work is its retrospective nature and
in particular the fact that tissue samples are collected only after
patients have received chemotherapy. This limits our ability to
ascribe causation to the findings we have demonstrated, and we are
only claiming an association between expression levels and injury
patterns as described.A more powerful investigation into the devel-
opment of CIHI requires the collection of tissue before treatment
with chemotherapy, and a comparison with tissue taken after
treatment. This work is currently underway in our laboratory.
Another limitation of any study assessing mRNA expression is
the potential that the protein level and protein activity and, there-
fore, effects on the cell may be determined by post-translational
events which may be more important than the mRNA expression
level. Nonetheless, mRNA expression has been used extensively for
these candidate genes. Further work correlating protein level and
protein activity with injury development validating the associa-
tions we have demonstrated here is warranted.
Conclusion
Low expression of hepatic DPD mRNA is associated with the
hepatic steatosis, particularly when associated with the adminis-
tration of chemotherapy. ERCC2 deserves further investigation as
a candidate enzyme associated with sinusoidal injury. It may be
possible to predict the development of such injury patterns based
on analyses such as these, linking candidate genes with injury
phenotypes.
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